16-12-2021, 08:21 AM
To analyse The French laboratory claims to have good results for its booster vaccine, but it must validate additional data, which causes a further delay.
At the end of September, the laboratory had also announced the end of research on a vaccine based on messenger RNA technology (such as those from Pfizer and Moderna ), considering it to be too late and had decided to focus on the booster vaccination.
Today, Olivier Bogillot, the president of Sanofi in France, however, wants to be reassuring. “ We will bring this vaccine next year. It may not be for a third dose. Maybe it will be for a fourth dose. " But " we will have a French vaccine " , he promises, affirming that " the virus is here for a long time " .
https://www.la-croix.com/Economie/Covid-...1201190350
At the end of September, the laboratory had also announced the end of research on a vaccine based on messenger RNA technology (such as those from Pfizer and Moderna ), considering it to be too late and had decided to focus on the booster vaccination.
Today, Olivier Bogillot, the president of Sanofi in France, however, wants to be reassuring. “ We will bring this vaccine next year. It may not be for a third dose. Maybe it will be for a fourth dose. " But " we will have a French vaccine " , he promises, affirming that " the virus is here for a long time " .
https://www.la-croix.com/Economie/Covid-...1201190350